Brief: 4DMT Announces FDA Clearance Of IND Application For 4D-175 Genetic Medicine For The Treatment Of Geographic Atrophy
24/06/2024 15:10
June 24 (Reuters) - 4D Molecular Therapeutics Inc
FDMT.O :
* 4DMT ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR 4D-175
GENETIC MEDICINE FOR THE TREATMENT OF GEOGRAPHIC ATROPHY
* 4D MOLECULAR THERAPEUTICS INC: ENROLLMENT FOR PHASE 1 GAZE
CLINICAL TRIAL TO BEGIN IN H2 2024
Source text for Eikon: ID:nGNX6FZQ9C
Further company coverage: FDMT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on 4D Molecular Therapeutics
See all news4D Molecular Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
4D Molecular Therapeutics Q2 net loss widens
Brief: 4D Molecular Therapeutics Q2 Net Income USD -72.936 Million Vs. IBES Estimate USD -70.3 Million
4D Molecular Therapeutics Inc expected to post a loss of $1.02 a share - Earnings Preview
Brief: 4d Molecular Therapeutics Says 4D-150 Continues To Be Well Tolerated With No New Safety Findings